Skip to main content

CD19 CAR T cell therapy alters disease-associated immune signatures in multiple sclerosis.

Cell

Authors: Felix Fischbach, Lena Kristina Pfeffer, Jan Broder Engler, Tradite Neziraj, Johanna Richter, Neda Sattarnezhad, Kristina Berve, Anne-Catherine Lecourt, Felix Schlicht, Franz F Konen, Jana K Sonner, Paul Saary, Anne Willing, Stefanie Reinhardt, Nina Meurs, Vanessa Vieira, Anita Badbaran, Carolina Berger, Dominic Borie, Johan Seibel, Jens Fiehler, Martin Daumer, Thomas Skripuletz, Jens Kuhle, Francis Ayuk, Christoph Heesen, Nicolaus Kröger, Boris Fehse, Tobias V Lanz, Anne-Katrin Pröbstel, Manuel A Friese

Multiple sclerosis (MS) is a chronic inflammatory central nervous system (CNS) disease. Although current immunotherapies control relapses, they have limited impact on progression, which might reflect incomplete access to or modulation of compartmentalized CNS inflammation. Chimeric antigen receptor (CAR) T cells can infiltrate tissues, but their ability to access and eliminate immune cells residing in the CNS remains elusive. We report the treatment of five individuals with progressive or relapsing-remitting MS with autologous CD19 CAR T cells to assess safety-relevant aspects, CNS bioavailability, and compartment-specific effects. The intervention induces remodeling of the cerebrospinal fluid (CSF) B cell pool, with a sustained reduction in CSF humoral biomarkers. Notably, CSF-infiltrating CAR T cells selectively upregulate phosphodiesterase 7B, while reconstituted peripheral B cells show altered cytokine and homing profiles. These findings indicate compartment-specific immunomodulation beyond peripheral B cell depletion and support controlled trials to test safety, durability, and efficacy.

Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved.

PMID: 43057228

Participating cluster members